Literature DB >> 25779886

A retrospective study of anastomotic leakage between patients with and without vascular enhancement of esophageal reconstructions with colon interposition: Thammasat University Hospital experience.

Surajit Awsakulsutthi1, Chittinad Havanond2.   

Abstract

BACKGROUND: Anastomotic leakage is a common complication after operative reconstruction with colon interposition in corrosive esophageal injury patients. Because the underlying causes are ischemic in nature, vascular enhancement would resolve this complication.
OBJECTIVE: To compare the incidence of anastomotic leakage between patients with and without vascular enhancement of esophageal reconstructions with colon interposition.
MATERIALS AND METHODS: This is a retrospective comparative study between patients with and without vascular enhancement during corrosive esophageal reconstructions with colon interposition in Thammasat University Hospital from January 2004 to December 2012.
RESULTS: Twenty-five adult patients who received esophageal reconstructions with colon interposition for corrosive esophageal injury were included in this study. Eleven of these patients also received vascular enhancement (classified as the "with vascular enhancement" group) during the reconstruction, whereas the remaining 14 patients did not (classified as the "without vascular enhancement" group). There was no significant difference in baseline characteristics of the patients between the two groups (i.e., sex, age, and preoperative hematocrit and serum albumin levels). There was also no significant difference in the leakage rate between the two groups: 35.7% (5/14) and 9% (1/11) in the without and with vascular enhancement groups, respectively (p = 0.180). However, in the "with vascular enhancement" group, the operative time was significantly longer (7.8 hours vs. 6.4 hours; an additional 1.4 hours), whereas length of hospital stay was shorter (18.3 days vs. 28.1 days; reduced by 9.8 days) compared with the other group.
CONCLUSIONS: Patients who received vascular enhancement along with colon interposition had a lower incidence of anastomotic leakage; however, there was no significant difference between the two groups in this study. Thus, further studies with a large sample size should be conducted in this regard.
Copyright © 2015. Published by Elsevier Taiwan.

Entities:  

Keywords:  colon interposition; corrosive esophageal reconstructions; vascular enhancement

Mesh:

Year:  2015        PMID: 25779886     DOI: 10.1016/j.asjsur.2015.01.005

Source DB:  PubMed          Journal:  Asian J Surg        ISSN: 1015-9584            Impact factor:   2.767


  5 in total

1.  A prospective randomized controlled trial of omeprazole for preventing esophageal stricture in grade 2b and 3a corrosive esophageal injuries.

Authors:  Prasit Mahawongkajit; Prakitpunthu Tomtitchong; Nuttorn Boochangkool; Chatchai Mingmalairak; Surajit Awsakulsutthi; Chittinad Havanond
Journal:  Surg Endosc       Date:  2020-06-15       Impact factor: 4.584

2.  Risk Factors for Esophageal Stricture in Grade 2b and 3a Corrosive Esophageal Injuries.

Authors:  Prasit Mahawongkajit; Prakitpunthu Tomtitchong; Nuttorn Boochangkool; Palin Limpavitayaporn; Amonpon Kanlerd; Chatchai Mingmalairak; Surajit Awsakulsutthi; Chittinad Havanond
Journal:  J Gastrointest Surg       Date:  2018-05-31       Impact factor: 3.452

3.  Comparison of Preoperative CT Colonography and Colonoscopy for Esophageal Reconstruction with Colonic Interposition.

Authors:  Prasit Mahawongkajit; Nuttorn Boochangkool
Journal:  Surg Res Pract       Date:  2020-11-16

4.  The Effect of the COVID-19 on Corrosive Ingestion in Thailand.

Authors:  Chatbadin Thongchuam; Prasit Mahawongkajit; Amonpon Kanlerd
Journal:  Open Access Emerg Med       Date:  2021-07-06

5.  Management of refractory cervical anastomotic fistula after esophagectomy using the pectoralis major myocutaneous flap.

Authors:  Lifei Deng; Yan Li; Weixiong Li; Muyuan Liu; Shaowei Xu; Hanwei Peng
Journal:  Braz J Otorhinolaryngol       Date:  2020-06-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.